Global Pleural Diseases Market expected to grow to USD 9.61 Billion by 2033, with a CAGR of 6.75%

From GlobeNewswire: 2024-06-22 01:00:00

The Global Pleural Diseases Market is set to grow from USD 5.0 Billion in 2023 to USD 9.61 Billion by 2033, with a CAGR of 6.75%. Pleural diseases affect the tissue lining the chest cavity and lungs, resulting from factors like infection and inflammation. The market is being driven by increasing respiratory conditions and a growing focus on tailored treatments.

Among the different types of pleural diseases are pneumothorax, pleural effusion, and pleurisy, which can be diagnosed through CT scans, chest x-rays, and blood tests. Specialized knowledge and resources are required for accurate diagnosis and treatment. The thoracentesis treatment segment dominates the market, offering opportunities for treating pleural diseases effectively.

Hospitals are the key end users in the global pleural diseases market, benefiting from increased funding for treatments and advanced medical equipment. North America holds the largest market share, with the United States leading due to healthcare spending and rising heart disease incidence. The Asia-Pacific region is expected to grow rapidly, driven by urbanization and increasing respiratory illnesses.

Major vendors in the pleural diseases market include Boston Medical, Pfizer CentreOne, Sanofi S.A., and others. Recent developments include Merck’s successful Phase 2/3 trial evaluating KEYTRUDA for malignant pleural mesothelioma. The market is segmented by treatment, end users, and regions, with the Asia-Pacific region showing significant growth potential. For more information on the market, visit Spherical Insights & Consulting.



Read more at GlobeNewswire: Global Pleural Diseases Market Size To Exceed USD 9.61